Development of Biomarkers and Prognosis Model of Mortality Risk in Patients with COVID-19
DOI: https://doi.org/10.2147/jir.s449497
IF: 4.5
2024-04-23
Journal of Inflammation Research
Abstract:Zhishuo Zhang, 1, &ast Lujia Tang, 1, &ast Yiran Guo, 1 Xin Guo, 2 Zhiying Pan, 2 Xiaojing Ji, 1, &ast Chengjin Gao 1, &ast 1 Department of Emergency, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China; 2 School of Information Science and Technology, Sanda University, Shanghai, Pudong District, 201209, China &astThese authors contributed equally to this work Correspondence: Xiaojing Ji; Chengjin Gao, Email ; Background: As of 30 April 2023, the COVID-19 pandemic has resulted in over 6.9 million deaths worldwide. The virus continues to spread and mutate, leading to continuously evolving pathological and physiological processes. It is imperative to reevaluate predictive factors for identifying the risk of early disease progression. Methods: A retrospective study was conducted on a cohort of 1379 COVID-19 patients who were discharged from Xin Hua Hospital affiliated with Shanghai Jiao Tong University School of Medicine between 15 December 2022 and 15 February 2023. Patient symptoms, comorbidities, demographics, vital signs, and laboratory test results were systematically documented. The dataset was split into testing and training sets, and 15 different machine learning algorithms were employed to construct prediction models. These models were assessed for accuracy and area under the receiver operating characteristic curve (AUROC), and the best-performing model was selected for further analysis. Results: AUROC for models generated by 15 machine learning algorithms all exceeded 90%, and the accuracy of 10 of them also surpassed 90%. Light Gradient Boosting model emerged as the optimal choice, with accuracy of 0.928 ± 0.0006 and an AUROC of 0.976 ± 0.0028. Notably, the factors with the greatest impact on in-hospital mortality were growth stimulation expressed gene 2 (ST2,19.3%), interleukin-8 (IL-8,17.2%), interleukin-6 (IL-6,6.4%), age (6.1%), NT-proBNP (5.1%), interleukin-2 receptor (IL-2R, 5%), troponin I (TNI,4.6%), congestive heart failure (3.3%) in Light Gradient Boosting model. Conclusion: ST-2, IL-8, IL-6, NT-proBNP, IL-2R, TNI, age and congestive heart failure were significant predictors of in-hospital mortality among COVID-19 patients. Keywords: COVID-19, machine learning, prognosis model, ST2, IL-8, TNI, IL-6, IL-2R, congestive heart failure It has been three years since the World Health Organization announced the definition of Coronavirus Disease 2019 (COVID-19) on 30 January 2020. The main clinical manifestations of patients with COVID-19 include fever, cough, pharyngalgia, etc. Some of these patients may develop into acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS), especially the elders or those patients with underlying diseases which can lead to fatal outcomes. As of 30 April 2023, the COVID-19 pandemic has resulted in over 6.9 million deaths worldwide. In December 2022, the Chinese government issued the new policy for the management of COVID-19. This policy led to a sudden increase in the number of newly infected patients, posing significant challenges to clinical work and experience. 1 The statistics information about COVID-19 can be downloaded at: https://covid19.who.int/ . Low lymphocyte (LYM) and white-blood-cell (WBC), high CRP and ferritin were effective in the diagnosis of COVID-19. 2,3 Indicators were found that high ESR, international-normalized-ratio (INR), prothrombin-time (PT), CRP, D-dimer, ferritin and red-cell-distribution width (RDW) values, respectively, were the most effective predictive mortality risk biomarkers of COVID-19. 4 The accurate and reliable estimation of Oxidant/Antioxidant levels in COVID-19 patients, utilizing biomarkers such as LYM, ferritin, D-dimer, WBC, and CRP, can facilitate the diagnosis and prognosis. 5 Most studies on COVID-19 were conducted during the initial outbreak, in which virus frequently mutated in the widespread, and genetic recombination occurs when different subtypes infect the human body. Gene mutation or recombination can affect virus's biological characteristics, 6, 7 influencing the whole pathophysiological process. Patients with severe pneumonia caused by COVID-19 infection can be challenging to reverse once the case develops into ARDS, so early identifying cases who may progress to severe are crucial. This study aims to statistically analyze the clinical data of infected cases during the special period, summarize clinical treatment experiences, and identify factors that may affect the prognosis, understand the characteristics of current viral inf -Abstract Truncated-
immunology